<DOC>
	<DOCNO>NCT01086917</DOCNO>
	<brief_summary>The study single center , vary dose , open label study . A maximum eighteen volunteer expose live NF54 P. falciparum sporozoite ( PfSPZ Challenge ) intradermal injection . Volunteers divide three group 6 volunteer , group space 25 day apart ( 21 day last challenge last volunteer previous dose group ) .</brief_summary>
	<brief_title>Experimental Human Malaria Infection PfSPZ</brief_title>
	<detailed_description>In every group day 1 , two volunteer inject . On day 3 remain four volunteer group inject . Injections subsequent volunteer always space least one hour apart group . Injection subsequent ( group ) volunteer commence previous injection show safe . Three different dos PfSPZ administer : dose 2,500 PfSPZ Challenge ( Group 1 ) ; dose 10,000 PfSPZ Challenge ( Group 2 ) volunteer become thick smear positive ( TS+ ) Group 1 ; dose 25,000 PfSPZ Challenge ( Group 3 ) 100 % TS+ Group 2 . If volunteer Group 1 ( 2,500 PfSPZ Challenge ) become thick smear positive , Group 2a receive 1,000 PfSPZ Challenge . If volunteer Group 2a become TS+ , volunteer Group 3a receive 500 PfSPZ Challenge . If volunteer Group 2 ( 10,000 PfSPZ Challenge ) become TS+ , Group 3b receive 5,000 PfSPZ . If less 100 % volunteer Group 2a ( 1,000 PfSPZ Challenge ) become TS+ Group 3c receive 1,750 PfSPZ Challenge . The clinical , biological , parasitological immunological data group ' volunteer compare . Volunteers investigator blind , laboratory personnel blind .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 35 year healthy volunteer ( male female ) 2 . Good health base history clinical examination 3 . Negative pregnancy test 4 . Use adequate contraception females 5 . All volunteer must sign informed consent form demonstrate understanding meaning procedure study 6 . Volunteer agree inform general practitioner agree sign request release medical information concern contraindication participation study 7 . Willingness undergo Pf sporozoite challenge 8 . For volunteer live Nijmegen : agreement stay hotel room close trial center part study ( Day 5 till 3 day treatment ) 9 . Reachable ( 24/7 ) mobile phone whole study period 10 . Living third party could contact clinician case alteration consciousness agreement stay hotel room close trial center part study ( Day 5 till 3 day treatment ) 11 . Available attend study visit 12 . Agreement refrain blood donation Sanquin purpose , study period day 140 . 13 . Willingness undergo HIV , hepatitis B hepatitis C test 14 . Negative urine toxicology screen test screen visit day challenge 15 . Willingness take curative regimen Malarone® 1 . History malaria 2 . Plans travel malaria endemic area 140 day study period 3 . Plans travel outside Netherlands day 028 study 4 . Previous participation malaria vaccine study and/or positive serology Pf 5 . Symptoms , physical sign laboratory value suggestive systemic disorder include renal , hepatic , cardiovascular , pulmonary , skin , immunodeficiency , psychiatric , condition could interfere interpretation study result compromise health volunteer 6 . History diabetes mellitus cancer ( except basal cell carcinoma skin ) 7 . History arrhythmia prolong QTinterval 8 . Positive family history 1st 2nd degree relative cardiac disease &lt; 50 year old 9 . An estimate , ten year risk fatal cardiovascular disease ≥5 % , estimate Systematic Coronary Risk Evaluation ( SCORE ) system 10 . Clinically significant abnormality electrocardiogram ( ECG ) screen 11 . Body Mass Index ( BMI ) 18 30 kg/m2 12 . Any clinically significant deviation normal range biochemistry hematology blood test urine analysis 13 . Positive HIV , HBV HCV test 14 . Participation clinical study within 30 day prior onset study 15 . Enrollment clinical study study period 16 . Pregnant lactate woman 17 . Volunteers unable give write informed consent 18 . Volunteers unable closely follow social , geographic psychological reason 19 . Previous history drug alcohol abuse interfere normal social function period one year prior enrolment study 20 . A history psychiatric disease 21 . Known hypersensitivity antimalaria drug 22 . The use chronic immunosuppressive drug , antibiotic , immune modifying drug within three month study onset ( inhaled topical corticosteroid allow ) study period 23 . Contraindications Malarone® include treatment take volunteer interfere Malarone® 24 . Any confirmed suspected immunosuppressive immunodeficient condition , include asplenia 25 . Coworkers department Medical Microbiology Internal Medicine Radboud University Nijmegen Medical Centre Sanaria Inc. 26 . A history sickle cell anemia , sickle cell trait , thalassemia , thalassemia trait G6PD deficiency</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Malaria Challenge</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Controlled human malaria infection</keyword>
	<keyword>PfSPZ Challenge</keyword>
</DOC>